Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients.
BACKGROUND
It has been suggested that iron increases oxidative stress and that an excess of iron contributes to cardiovascular disease and infections in haemodialysis patients. In the present study, the effects of parenterally administered iron on leucocyte surface molecule expression and the production of reactive oxygen species (ROS) were evaluated.


METHODS
Ten chronic haemodialysis (HD) patients without iron overload were studied. To each patient, four different regimens were applied: placebo; iron sucrose, either 30 or 100 mg, administered via the outflow dialyser line; and 100 mg of iron sucrose infused via the inflow dialyser line. Blood was sampled at different time points: before, during and after infusion and immediately before the next dialysis session. Levels of CD11b and CD45 expression on granulocytes and of CD11b, CD14 and CD36 on monocytes were determined using flow cytometric analysis. The generation of ROS was quantified using chemiluminescence with and without ex vivo stimulation by phorbol myristate acetate (PMA).


RESULTS
No significant differences among the four different treatment regimes were found, neither in chemilumescence activity nor in the expression of CD11b and CD45 on granulocytes, and of CD11b, CD14 and CD36 on monocytes.


CONCLUSIONS
Our results suggest that parenteral infusion of iron sucrose during haemodialysis in patients who have no signs of iron overload has no significant effect on the expression of leucocyte surface molecules and does not increase production of ROS.
Guz
Galip
G
Department of Nephrology, Ghent University Hospital, Ghent, Belgium. galip_guz@hotmail.com
Glorieux
Griet L
GL
De Smet
Rita
R
Waterloos
Marie-Anne F
MA
Vanholder
Raymond C
RC
Dhondt
Annemieke W
AW
D000368:Aged; D039481:CD11b Antigen / Q000032:analysis; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D000077605:Ferric Oxide, Saccharated; D005434:Flow Cytometry; D005937:Glucaric Acid; D006098:Granulocytes / Q000187:drug effects / Q000378:metabolism; D006397:Hematinics / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D017493:Leukocyte Common Antigens / Q000032:analysis; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D049449:Luminescence; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000097:blood* / Q000737:chemistry; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000097:blood / Q000628:therapy
D039481:CD11b Antigen; D005290:Ferric Compounds; D006397:Hematinics; D018950:Lipopolysaccharide Receptors; D017382:Reactive Oxygen Species; D017493:Leukocyte Common Antigens; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid